Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25

Suraksha Diagnostic reports Q1 FY26 PAT higher by 20% at Rs. 9.1 Cr

WACKER and Gearbox Biosciences collaborate to advance pDNA manufacturing technologies

The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025

Primelaze introduces Q-Switched Nd:YAG laser technology in India for skin treatments

The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore

Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter

Sandoz to acquire Just–Evotec Biologics facility for $300 million

The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results